Xiaohua Sheng

Safety and Immunogenicity of Tetanus-Diphtheria-Acellular Pertussis Vaccine Administered to Children 10 or 11 Years of Age

M. Decker, D. Greenberg, David R. Johnson, 2014, Clinical and Vaccine Immunology.

Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.

W. A. Brooks, Lee-Jah Chang, R. Hopfer, 2015, Vaccine.

Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4–6 Years of Age

Michael J. Smith, E. Jordanov, Peter H Tsang, 2017, The Pediatric infectious disease journal.

Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.

S. Gurunathan, M. Bologa, R. Hopfer, 2012, Vaccine.

Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.

S. Gurunathan, D. Neveu, M. Bologa, 2013, Vaccine.